FTSV stock forecast
Our latest prediction for Forty Seven, Inc.'s stock price was made on the July 22, 2019 when the stock price was at 8.81$.
In the short term (2weeks), FTSV's stock price should outperform the market by 5.95%. During that period the price should oscillate between -7.96% and +15.02%.
In the medium term (3months), FTSV's stock price should outperform the market by 6.02%. During that period the price should oscillate between -19.55% and +36.03%.Get email alerts
About Forty Seven, Inc.
Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.47$ per share.
The book value per share is 3.60$
Three months stock forecastJuly 22, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|